Lennart Friis-Hansen

Dr. Lennart Friis-Hansen


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2009 in The Lancet Oncology
Verified
Journal Article
Closed access
FMFred H Menko
Fred H Menko
MSMaurice A.M. van Steensel
Maurice A.M. van Steensel
SGSophie Giraud
Sophie Giraud
LFLennart Friis-Hansen
Lennart Friis-Hansen
SRStéphane Richard
Stéphane Richard
EMEamonn Richard Maher
Eamonn Richard Maher

1 October 2001 in Cell
Verified
Journal Article
Closed access
BPBo T. Porse
Bo T. Porse
TPThomas Å. Pedersen
Thomas Å. Pedersen
XXXiufeng Xu
Xiufeng Xu
BLBo Lindberg
Bo Lindberg
UWUlla M. Wewer
Ulla M. Wewer
CNClaus Nerlov
Claus Nerlov

3 April 2012 in British Journal of Cancer
Verified
Journal Article
Open access
CLC B Lajer
C B Lajer
EGE Garnæs
E Garnæs
LFLennart Friis-Hansen
Lennart Friis-Hansen
BNB Norrild
B Norrild
MTM H Therkildsen
M H Therkildsen
FNF C Nielsen
F C Nielsen
Background: Methods: Results: Conclusion:

18 March 2011 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
TKTony Bou Kheir
Tony Bou Kheir
EFEwa Futoma-Kazmierczak
Ewa Futoma-Kazmierczak
AJAnders Jacobsen
Anders Jacobsen
AKAnders Krogh
Anders Krogh
LBLinda Bardram
Linda Bardram
LFLennart Friis-Hansen
Lennart Friis-Hansen
Background: Gastric cancer is the fourth most common cancer in the world and the second most prevalent cause of cancer related death. The development of gastric cancer is mainly associated with H. Pylori infection leading to a focus in pathology studies on bacterial and environmental factors, and to a lesser extent on the mechanistic development of the tumour. MicroRNAs are small non-coding RNA molecules involved in post-transcriptional gene regulation. They are found to regulate genes involved in diverse biological functions and alterations in microRNA expression have been linked to the pathogenesis of many malignancies. The current study is focused on identifying microRNAs involved in gastric carcinogenesis and to explore their mechanistic relevance by characterizing their targets. Results: Invitrogen NCode miRNA microarrays identified miR-449 to be decreased in 1-year-old Gastrin KO mice and in H. Pylori infected gastric tissues compared to tissues from wild type animals. Growth rate of gastric cell lines over-expressing miR-449 was inhibited by 60% compared to controls. FACS cell cycle analysis of miR-449 over-expressing cells showed a significant increase in the sub-G1 fraction indicative of apoptosis. ß-Gal assays indicated a senescent phenotype of gastric cell lines over-expressing miR-449. Affymetrix 133v2 arrays identified GMNN, MET, CCNE2, SIRT1 and CDK6 as miR-449 targets. Luciferase assays were used to confirm GMNN, MET, CCNE2 and SIRT1 as direct targets. We also show that miR-449 over-expression activated p53 and its downstream target p21 as well as the apoptosis markers cleaved CASP3 and PARP. Importantly, qPCR analyses showed a loss of miR-449 expression in human clinical gastric tumours compared to normal tissues. Conclusions: In this study, we document a diminished expression of miR-449 in Gastrin KO mice and further confirmed its loss in human gastric tumours. We investigated the function of miR-449 by identifying its direct targets. Furthermore we show that miR-449 induces senescence and apoptosis by activating the p53 pathway.

15 February 2011 in British Journal of Cancer
Verified
Journal Article
Open access
CLC B Lajer
C B Lajer
FNF C Nielsen
F C Nielsen
LFLennart Friis-Hansen
Lennart Friis-Hansen
BNB Norrild
B Norrild
RBR Borup
R Borup
Christian von BuchwaldChristian von Buchwald
Christian von Buchwald
Background: Methods: Results: Conclusion:

1 June 2007 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
JRJens F. Rehfeld
Jens F. Rehfeld
LFLennart Friis-Hansen
Lennart Friis-Hansen
JGJens P. Goetze
Jens P. Goetze
THThomas V. O. Hansen
Thomas V. O. Hansen
Cholecystokinin (CCK) and gastrin together constitute a family of homologous peptide hormones, which are both physiological ligands for the gastrin/CCK-B receptor, whereas the CCK-A receptor binds only sulfated CCKpeptides. CCK peptides are mainly produced in small intestinal endocrine I-cells and in cerebral neurons. CCK peptides regulate pancreatic enzyme secretion and growth, gallbladder contraction, intestinal motility, satiety and inhibit gastric acid secretion. Moreover, they are potent neurotransmitters in the brain and the periphery. CCK peptides are derived from proCCK and have the bioactive heptasequence -Tyr(SO4)-Met-Gly-Trp-Met-Asp-Phe-NH2 as their C-terminus. The dominant forms in plasma are CCK-58, CCK-33, CCK-22 and CCK-8, whereas CCK-8 is the major transmitterform. Due to scarcity of specific assays, knowledge about CCK in disease is still limited. Gastrin peptides are mainly synthetized in antroduodenal G-cells, from where they are released to blood to regulate gastric acid secretion and mucosal growth. Small amounts are synthetized further down the intestinal tract, in the foetal pancreas, in a few cerebral and peripheral neurons, in the pituitary gland and in spermatozoes. Gastrin peptides are derived from progastrin and all have the C-terminal bioactive hexasequence -Tyr (SO4)-Gly-Trp-Met-Asp-Phe-NH2. The major gastrin forms in tissue and plasma are gastrin- 34 and gastrin-17, but also gastrin-71, -14 and -6 have been identified. Gastrin peptides are secreted in excessive amounts from gastrinomas and are expressed at lower levels in bronchogenic, colorectal, gastric, ovarian and pancreatic cancers. A carcinogenetic significance of gastrin peptides remains, however, to be proven.